Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

March 01, 2003; Volume 31,Issue 3

Short Communication

  • You have access
    Assessment of the Contributions of CYP3A4 and CYP3A5 in the Metabolism of the Antipsychotic Agent Haloperidol to Its Potentially Neurotoxic Pyridinium Metabolite and Effect of Antidepressants on the Bioactivation Pathway
    Amit S. Kalgutkar, Timothy J. Taylor, Karthik Venkatakrishnan and Emre M. Isin
    Drug Metabolism and Disposition March 2003, 31 (3) 243-249; DOI: https://doi.org/10.1124/dmd.31.3.243

Articles

  • You have access
    Molecular Modeling and Metabolic Studies of The Interaction of Catechol-O-Methyltransferase and a New Nitrocatechol Inhibitor
    P. N. Palma, M. J. Bonifácio, A. I. Loureiro, L. C. Wright, D. A. Learmonth and P. Soares-da-Silva
    Drug Metabolism and Disposition March 2003, 31 (3) 250-258; DOI: https://doi.org/10.1124/dmd.31.3.250
  • You have access
    CYP1A1 and CYP1B1 in Blood-Brain Interfaces: CYP1A1-Dependent Bioactivation of 7,12-Dimethylbenz(a)anthracene in Endothelial Cells
    Lizette Granberg, Anna Östergren, Ingvar Brandt and Eva B. Brittebo
    Drug Metabolism and Disposition March 2003, 31 (3) 259-265; DOI: https://doi.org/10.1124/dmd.31.3.259
  • You have access
    Metabolism of Chloroform in the Human Liver and Identification of the Competent P450s
    Simonetta Gemma, Luciano Vittozzi and Emanuela Testai
    Drug Metabolism and Disposition March 2003, 31 (3) 266-274; DOI: https://doi.org/10.1124/dmd.31.3.266
  • You have access
    Oxidative Metabolism of Amprenavir in the Human Liver. Effect of the CYP3A Maturation
    J. M. Tréluyer, G. Bowers, N. Cazali, M. Sonnier, E. Rey, G. Pons and T. Cresteil
    Drug Metabolism and Disposition March 2003, 31 (3) 275-281; DOI: https://doi.org/10.1124/dmd.31.3.275
  • You have access
    Induction of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices
    Robert J. Edwards, Roger J. Price, Patricia S. Watts, Anthony B. Renwick, J. Michael Tredger, Alan R. Boobis and Brian G. Lake
    Drug Metabolism and Disposition March 2003, 31 (3) 282-288; DOI: https://doi.org/10.1124/dmd.31.3.282
  • You have access
    Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine
    Kirk M. Bertelsen, Karthik Venkatakrishnan, Lisa L. von Moltke, R. Scott Obach and David J. Greenblatt
    Drug Metabolism and Disposition March 2003, 31 (3) 289-293; DOI: https://doi.org/10.1124/dmd.31.3.289
  • You have access
    Absorption, Distribution, Metabolism, and Excretion of Ximelagatran, an Oral Direct Thrombin Inhibitor, in Rats, Dogs, and Humans
    Ulf G. Eriksson, Ulf Bredberg, Kurt-Jürgen Hoffmann, Anneli Thuresson, Margareth Gabrielsson, Hans Ericsson, Martin Ahnoff, Kristina Gislén, Gunnar Fager and David Gustafsson
    Drug Metabolism and Disposition March 2003, 31 (3) 294-305; DOI: https://doi.org/10.1124/dmd.31.3.294
  • You have access
    Identification of Trichloroethylene and Its Metabolites in Human Seminal Fluid of Workers Exposed to Trichloroethylene
    Poh-Gek Forkert, Lawrence Lash, Robert Tardif, Nongnuj Tanphaichitr, Catherine Vandevoort and Madeleine Moussa
    Drug Metabolism and Disposition March 2003, 31 (3) 306-311; DOI: https://doi.org/10.1124/dmd.31.3.306
  • You have access
    P-Glycoprotein Limits the Brain Penetration of Nonsedating but not Sedating H1-Antagonists
    Cuiping Chen, Elizabeth Hanson, John W. Watson and Jae S. Lee
    Drug Metabolism and Disposition March 2003, 31 (3) 312-318; DOI: https://doi.org/10.1124/dmd.31.3.312
  • You have access
    Effect of Efflux Inhibition on Brain Uptake of Itraconazole in Mice Infected with Cryptococcus neoformans
    Frédéric Imbert, Méryam Jardin, Christine Fernandez, Jean Charles Gantier, Françoise Dromer, Gabriel Baron, France Mentre, Ludy van Beijsterveldt, Eric Singlas and François Gimenez
    Drug Metabolism and Disposition March 2003, 31 (3) 319-325; DOI: https://doi.org/10.1124/dmd.31.3.319
  • You have access
    Tissue mRNA Expression of the Rat UDP-Glucuronosyltransferase Gene Family
    M. K. Shelby, N. J. Cherrington, N. R. Vansell and C. D. Klaassen
    Drug Metabolism and Disposition March 2003, 31 (3) 326-333; DOI: https://doi.org/10.1124/dmd.31.3.326
  • You have access
    Metabolism and Disposition of the Antihypertensive Agent Moxonidine in Humans
    Minxia M. He, Trent L. Abraham, Thomas J. Lindsay, Hans C. Schaefer, Isabelle J. Pouliquen, Chris Payne, Boris Czeskis, Lisa A. Shipley, Stuart D. Oliver and Malcolm I. Mitchell
    Drug Metabolism and Disposition March 2003, 31 (3) 334-342; DOI: https://doi.org/10.1124/dmd.31.3.334

Letter to the Editor

  • You have access
    Verification of the Selectivity of (+)N-3-Benzylnirvanol as a CYP2C19 Inhibitor
    Robert L. Walsky and R. Scott Obach
    Drug Metabolism and Disposition March 2003, 31 (3) 343; DOI: https://doi.org/10.1124/dmd.31.3.343
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition: 31 (3)
Drug Metabolism and Disposition
Vol. 31, Issue 3
1 Mar 2003
  • Table of Contents
  • About the Cover
  • Index by author
Sign up for alerts

Jump to

  • Short Communication
  • Articles
  • Letter to the Editor
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics